The approach was in line with that of the authors who treated patients with symptomatic hyperprolactinaemia, by switching to a non-prolactin-elevating drug (clozapine, olanzapine, quetiapine, aripiprazole, or ziprasidone).[19–21] The dopamine agonists (Amantadine, Cabergoline, and Bromocriptine) may be effective but have the potential to worsen psychosis.[20–22] There is partial change in the psychopathology during the first two weeks of trial of amisulpride 50 mg/day, but the side effect of hyperprolactinaemia outweighs the therapeutic benefit. The gene discussed is PRL; the disease is hyperprolactinemia.